Bioventus Affirms FY2025 Adj EPS Guidance of $0.64-$0.68 vs $0.71 Est; Affirms FY2025 Sales Guidance of $560.000M-$570.000M vs $565.200M Est

Author: Benzinga Newsdesk | August 06, 2025 06:05am

2025 Financial Guidance:

Bioventus reiterated its 2025 Financial Guidance provided on May 6, 2025, including an estimated impact of tariffs, which is immaterial at this time. For the twelve months ending December 31, 2025, the Company continues to expect:

• Net sales of $560 million to $570 million. This reflects organic* growth of approximately 6.1% to 8.0% when including the impact of the Company's divestiture of its Advanced Rehabilitation Business, which generated revenue of $45.4 million in 2024.
• Adjusted EBITDA* of $112 million to $116 million, reflecting 100 basis points in Adjusted EBITDA Margin* growth compared to the 2024 Adjusted EBITDA Margin* of 19.0% when using the low end of the 2025 revenue and Adjusted EBITDA* guidance. The guidance assumes the Company will continue to successfully offset the combined $5 million related to foreign exchange expense, which occurred throughout the first half of the year, and the full year expected impact of current tariffs. The guidance does not assume additional impact from U.S. dollar fluctuation in the second half of the year.
• Non-GAAP EPS* of $0.64 to $0.68, reflecting an increase of 30.6% to 38.8%.

Posted In: BVS